double homeobox 4 like 50 (pseudogene)Genealiases: []
Q-omics provides the consensus-scored DUX4L50 profile across patient tissues and cancer cell-line models. DUX4L50 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DUX4L50 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, DUX4L50 RNA expression shows 17,169 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where DUX4L50 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DUX4L50 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DUX4L50 survival associations across molecular data types. DUX4L50 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DUX4L50 RNA expression–survival associations across cancer types. High DUX4L50 expression shows unfavorable associations in KIRC, ACC, UCEC and DLBC, but favorable associations in UCS and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DUX4L50 RNA expression.
This table summarizes DUX4L50 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DUX4L50. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DUX4L50 shows higher tumor expression in KIRC, BLCA, HNSC, KIRP, LUSC and UCEC. The KIRC box plot shows higher DUX4L50 RNA expression in tumor versus normal tissue (log2 FC = +0.741, t-test p < 0.001).
This table shows molecular features associated with DUX4L50 in patient tissues and cancer cell lines. In patient samples, DUX4L50 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
